Total Raised

$120.58M

Investors Count

8

Deal Terms

3

Funding, Valuation & Revenue

9 Fundings

Optinose has raised $120.58M over 9 rounds.

Optinose's latest funding round was a Take Private for on May 21, 2025.

Optinose's valuation in October 2017 was $566.18M.

Optinose's latest post-money valuation is from May 2025.

Sign up for a free demo to see Optinose's valuations in May 2025 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/21/2025

Take Private

$XXM

$X.XXB

((X.XXx))

FY XXXX

6

10/12/2017

IPO

$XXM

$566.18M

0

FY undefined

10

4/7/2017

Series E

$XXM

$XXM

0

FY undefined

10

10/6/2015

Series D

$XXM

$XXM

0

FY undefined

10

8/4/2014

Series C - II

$XXM

$XXM

0

FY undefined

10

Date

5/21/2025

10/12/2017

4/7/2017

10/6/2015

8/4/2014

Round

Take Private

IPO

Series E

Series D

Series C - II

Amount

$XXM

$XXM

$XXM

$XXM

Investors

Valuation

$XXM

$566.18M

$XXM

$XXM

$XXM

Revenue

$X.XXB

((X.XXx))

FY XXXX

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

6

10

10

10

10

Start free trial
New call-to-action

Optinose Deal Terms

3 Deal Terms

Optinose's deal structure is available for 3 funding rounds, including their Take Private from May 21, 2025.

Round

Take Private

IPO

Series A

Funding Date

$XXM

$XXM

$XXM

Pre-Money Valuation

$XXM

Post-Money Valuation

$XXM

$XXM

Amount Raised

$XXM

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Take Private

$XXM

$XXM

$XXM

$XXM

IPO

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

Optinose Investors

8 Investors

Optinose has 8 investors. Paratek Pharmaceuticals invested in Optinose's Take Private funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

5/21/2025

5/21/2025

1
Take Private

Corporation

Massachusetts

00/00/0000

00/00/0000

Avista Healthcare Partners

Subscribe to see more

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

Entrepreneurs Fund

Subscribe to see more

Venture Capital

United Kingdom

00/00/0000

00/00/0000

WFD Ventures

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Fidelity Investments

Subscribe to see more

Investment Bank

Massachusetts

First funding

5/21/2025

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

5/21/2025

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Avista Healthcare Partners

Entrepreneurs Fund

WFD Ventures

Fidelity Investments

Rounds

1
Take Private

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Type

Corporation

Private Equity

Venture Capital

Venture Capital

Investment Bank

Location

Massachusetts

New York

United Kingdom

New York

Massachusetts

New call-to-action

Compare Optinose to Competitors

F
FORMAC Pharmaceuticals N.V.

FORMAC Pharmaceuticals N.V. is a company engaged in the pharmaceutical industry. The company specializes in silica-based drug delivery platforms intended to improve the performance of poorly soluble drugs. FORMAC Pharmaceuticals collaborates with pharmaceutical and animal health companies. It was founded in 2007 and is based in Belgium.

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

F
Felton International

Pulse NeedleFree Systems is a medical technology company focused on development of needle-free pharmaceutical injection systems for the animal health and human health industries. Pulse's animal health injection systems are marketed to large livestock producers in the United States and select international markets.

I
Imagine Pharmaceuticals

Imagine Pharmaceuticals is developing technology to facilitate delivery of drugs to the brain

T
Travanti Pharma

Travanti Pharma is a medical device company specializing in the development and sale of microneedle array products for the healthcare sector. Their main offering includes the AdminPen2 hollow microneedle injection device, designed for self-administrable drug delivery without the need for reformulating existing drug formulations. The company primarily serves sectors that require drug delivery solutions, such as oncology, immunology, and transdermal therapy. It was founded in 1997 and is based in Mendota Heights, Minnesota.

Next Breath Logo
Next Breath

Next Breath is involved in the development and analytical testing of inhalation and nasal drug products within the pharmaceutical industry. The company provides services including pharmaceutical formulation, CMC testing, finished batch release, post-approval stability, and regulatory submissions support. Next Breath serves pharmaceutical, biotech, and medical device companies with a focus on inhalation and nasal delivery systems. It is based in Baltimore, Maryland.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.